Resumen
Prostate cancer (PCa) is the most frequent malignancy, and the second leading cause of cancer-related death, in men in the United States. PCa detection has been largely determined by the widely used prostate-specific antigen (PSA) blood test, followed by biopsy for a definitive diagnosis. Over the past years, more refined and more specific blood-based assays, as well as urine-based PCa tests, have driven remarkable progress in PCa detection and prognosis. Urine-based ?liquid biopsies? provide minimally invasive, or non-invasive, options for the early detection and risk stratification of PCa. This mini review highlights current advancements and future perspectives.